What Alzheon does

Alzheon is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Framingham, Massachusetts, that is developing oral small-molecule disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders. Its lead asset, valiltramiprosate/ALZ-801, is a valine-conjugated prodrug of tramiprosate that uses a novel enveloping molecular mechanism to fully block formation of neurotoxic soluble beta amyloid oligomers without affecting insoluble plaques or fibrils. The program is supported by an internally discovered endogenous metabolite, 3-sulfopropanoic acid (3-SPA), which contributes to brain penetration and selectivity. A second oral candidate, ALZ-507, entered a Phase 1 trial in April 2026 with an APOE4 corrector mechanism and potential once-daily dosing.

The company employs a precision medicine strategy, initially targeting Early Alzheimer's disease patients homozygous for the APOE4/4 genotype (approximately 15% of AD patients), with planned expansion to APOE3/4 heterozygotes and to prevention settings. The pivotal APOLLOE4 Phase 3 trial enrolled 325 APOE4/4 homozygotes over 78 weeks in North America and Europe; topline results in April 2025 showed cognitive and functional benefit in prespecified analyses in the mild cognitive impairment subgroup, and full results were peer-reviewed in Drugs in October 2025. ALZ-801 has carried FDA Fast Track designation since 2017.

Alzheon's business model is currently pre-revenue and built around advancing its pipeline toward U.S. commercialization of ALZ-801 in 2025, supported by a $100 million Series E (June 2024), a prior $50 million Series D (April 2022), and $51 million in grants from the National Institute on Aging. The company is constructing a U.S. direct sales and market access organization under a newly appointed Chief Commercial Officer with prior launch experience at Biogen, Genentech, J&J, and AstraZeneca. Revenue mechanics will rely on prescription pharmaceutical sales to healthcare providers and payers once approval is secured; pricing has not been publicly disclosed and no licensing revenue has been reported.

Name

Alzheon

Legal name

Alzheon, Inc.

Website

https://alzheon.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Alzheon is a clinical-stage biopharmaceutical company developing oral anti-amyloid oligomer small molecules, led by valiltramiprosate (ALZ-801) in Phase 3 for Early Alzheimer's disease in APOE4/4 homozygotes, preparing for a U.S. commercial launch.

Ownership category

akta.pro rank

Headquarters

HQ city

Framingham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Alzheon plans to commercialize oral valiltramiprosate/ALZ-801 as a disease-modifying treatment for Alzheimer's disease following regulatory approval. Expected commercial launch in 2025 pending successful Phase 3 trial completion and NDA submission.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Alzheon is developing valiltramiprosate/ALZ-801, an investigational oral anti-amyloid oligomer treatment for Early Alzheimer's disease, with initial focus on APOE4/4 homozygote patients. The product blocks formation of neurotoxic soluble beta amyloid oligomers through a novel enveloping molecular mechanism of action without binding to amyloid plaques. The company has completed Phase 3 APOLLOE4 testing and is preparing for potential regulatory approval and U.S. commercial launch.

Product overview

Alzheon is a clinical-stage biopharmaceutical company developing a portfolio of product candidates for Alzheimer's disease and other neurodegenerative disorders. The lead product is valiltramiprosate/ALZ-801, an oral anti-amyloid agent in Phase 3 development targeting neurotoxic beta amyloid oligomers in early Alzheimer's disease patients, particularly APOE4/4 homozygotes. The company also has ALZ-507 in Phase 1 development and maintains a discovery platform of small molecules using precision medicine approaches. The company is preparing for potential regulatory filings and commercialization of ALZ-801 with expected U.S. market launch in 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Valiltramiprosate/ALZ-801 Valiltramiprosate/ALZ-801 is an investigational first-in-class oral anti-amyloid agent that blocks formation of neurotoxic soluble beta amyloid oligomers through a novel enveloping molecular mechanism of action, without binding to amyloid plaques or causing vasogenic brain edema. It is being developed as a disease-modifying treatment for Early Alzheimer's disease, with initial focus on patients homozygous for the APOE4/4 genotype who are 8-12 times more likely to develop AD. The oral tablet formulation crosses the blood-brain barrier efficiently and enables convenient at-home administration.
• ALZ-507 ALZ-507 is an oral drug candidate in Phase 1 development for Alzheimer's disease that targets amyloid aggregation with an additional APOE4 corrector mechanism. It is designed for potential once-daily administration with improved safety and efficacy compared to existing anti-amyloid therapies.

Quantifiable outcome

• 31% reduction in plasma P-tau181 at 24 months in Phase 2 trial
• +3 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Bellus HealthcoreTechnology or IntegrationALZ-801/valiltramiprosate was licensed from Bellus Health. The drug is an optimized prodrug of tramiprosate originally developed by Bellus Health.
• EisaiminorStrategic or Co-development PartnerAt the AD/PD annual meeting, both companies presented data on treatments targeting high-risk Alzheimer's patients with APOE4 genetic profiles. Both focus on improving treatment options for genetically defined populations.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Prothena: Clinical-stage biotechnology company developing protein immunotherapy approaches for Alzheimer's disease and other neurodegenerative disorders, including anti-amyloid antibodies. Comparable as a clinical-stage AD-focused biotech with overlapping target biology.
• AC Immune: Clinical-stage biopharmaceutical company developing therapeutics for Alzheimer's disease and neurodegenerative disorders, with both small molecule and vaccine approaches. Comparable as a clinical-stage AD biotech with multiple pipeline assets targeting amyloid and tau.
• Cognition Therapeutics: Clinical-stage company developing CT1812, an oral small molecule for Alzheimer's disease and other neurodegenerative disorders. Comparable as a similarly-staged AD biotech focused on synaptic and oligomer-related mechanisms.
• Anavex Life Sciences: Clinical-stage biotechnology company developing blarcamesine (ANAVEX2-73), an oral small molecule for Alzheimer's disease and other neurodegenerative disorders. Directly comparable as a clinical-stage CNS biotech with similar development profile and oral small molecule approach.
• Cassava Sciences: Clinical-stage biotechnology company developing simufilam, an oral small molecule for Alzheimer's disease. Directly comparable to Alzheon as a similarly-sized private/public clinical-stage AD therapeutics company targeting oral disease-modifying mechanisms.

Emerging players

• Vigil Neuroscience: Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases, with a focus on TREM2 agonist and microglia-targeting approaches. Comparable as an emerging clinical-stage neurodegeneration biotech with similar stage and target indication space.
• Denali Therapeutics: Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's, with a focus on small molecules and biologics that cross the blood-brain barrier. Comparable as an emerging clinical-stage CNS biotech with similar BBB-penetration and neurodegeneration focus.

Broad incumbents

• Biogen: Large biopharmaceutical company with marketed Alzheimer's therapies including Aduhelm and co-developed Leqembi. Comparable as the established incumbent in the AD therapeutics space, against which Alzheon's oral therapy must differentiate.
• Eli Lilly: Global pharmaceutical company that markets Kisunla (donanemab) for early symptomatic Alzheimer's disease. Comparable as a broad incumbent in AD therapeutics with an approved anti-amyloid antibody competing with Alzheon's oral approach.
• Eisai: Global pharmaceutical company that co-developed and markets Leqembi (lecanemab) for Alzheimer's disease. Comparable as the leading commercialized AD therapeutics incumbent and a co-development partner cited in Alzheon's industry engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/alzheon
• LinkedInlinkedin.com/company/alzheon

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds12 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzheon